Investigational New Drugs 2020-Jul
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Länken sparas på Urklipp
Nyckelord
Abstrakt
Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.
Keywords: Allergic acute tubulointerstitial nephritis; Medullary thyroid carcinoma; Tyrosine kinase inhibitor; Vandetanib.